Valeant And Pershing May Sweeten Allergan Deal By $15 A ShareMani
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Bill Ackman’s Pershing Square are said to be planning to boost their offer to acquire Botox maker Allergan, Inc. (NYSE:AGN) by $15 a share, according to people familiar with the developments.
The enhanced offer marks Valeant and Pershing Square’s third increase to their original bid.
Valeant - Allergan merger could be the largest deal of the year
The latest bid from Valeant Pharmaceuticals and Pershing is intended to keep the Botox maker . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.